Andy Pasternak - 09 Sep 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
EVP and Chief Business Officer
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Sep 2021
Net transactions value
-$1,820,921
Form type
4
Filing time
13 Sep 2021, 20:00:16 UTC
Previous filing
30 Jul 2021
Next filing
03 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise $686,340 +23,250 +100% $29.52 46,604 09 Sep 2021 Direct
transaction HZNP Ordinary Shares Sale $2,453,564 -22,754 -49% $107.83 23,850 09 Sep 2021 Direct F1, F2
transaction HZNP Ordinary Shares Sale $53,697 -496 -2.1% $108.26 23,354 09 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -23,250 -33% $0.000000 46,502 09 Sep 2021 Ordinary Shares 23,250 $29.52 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.235 to $108.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option is fully vested and exercisable.